NCT06085924

A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.

Real World Evaluation of COVID-19 Burden and Nirmatrelvir/Ritonavir in Taiwan Using National Health Insurance Research Database

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8,252,912 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 0 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan. In Group 1 the below participants were included in the study: * Patients of all ages. * Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. * Cases of patients registered in the databases. In Group 2 the below participants were included in the study: * Participants who are 12 years or older. * Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022. Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19. The study will look at: * the nature of Covid-19 disease. * as well as the experiences of people receiving the nirmatrelvir-ritonavir. This study will help to: * understand what type of patients will need to be admitted to hospitals. * see severe results due to COVID 19 infection. * have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	SoC	COVID-19 treatment as per government guidance
OTHER	Disease description	No intervention

Timeline

• Start date: 2023-11-07
• Primary completion: 2025-02-28
• Completion: 2025-02-28
• First posted: 2023-10-17
• Last updated: 2025-11-25

Locations

1 site across 1 country: Taiwan

Regulatory

• FDA-regulated drug study